Literature DB >> 9022698

The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.

H Bergler1, S Fuchsbichler, G Högenauer, F Turnowsky.   

Abstract

Reduction of enoyl-acyl-carrier-protein (ACP) substrates by enoyl-ACP reductase is a key regulatory step in fatty acid elongation of Escherichia coli. Two enoyl-ACP reductase activities have been described in E. coli, one specific for NADH, the other for NADPH as cofactor. Because of their distinct enzymatic properties, these activities were ascribed to two different proteins. The NADH-dependent enoyl-ACP reductase of E. coli has previously been identified as the FabI protein, which is the target of a group of antibacterial compounds, the diazaborines. We now demonstrate that both enoyl-ACP reductase activities reside in FabI. In crude cell extracts of FabI-overproducing strains, both NADH-dependent and NADPH-dependent enoyl-ACP reductase activities are increased. Mutations in the fabI gene that lead either to temperature-sensitive growth or diazaborine resistance result in the reduction of both activities. When FabI is purified in pH 6.5 buffers, the protein exhibits NADH-dependent and NADPH-dependent reductase activities. Both enzymatic activities are inhibited by diazaborine. The NADPH-dependent enoyl-ACP reductase activity, however, turned out to be approximately eight times more resistant to diazaborine. The difference in sensitivity indicates that binding of either NADPH or NADH to FabI results in distinct changes in the configuration of the protein or, alternatively, it is different due to the different charge of the cofactors. These effects might be responsible for the differences in the enzymatic properties. Both reductase activities of the FabI protein are inhibited by physiologically relevant concentrations of palmitoyl-CoA, which might be important in regulating endogenous fatty acid biosynthesis in E. coli in the presence of exogenous fatty acids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9022698     DOI: 10.1111/j.1432-1033.1996.0689r.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  49 in total

Review 1.  Fatty acid biosynthesis revisited: structure elucidation and metabolic engineering.

Authors:  Joris Beld; D John Lee; Michael D Burkart
Journal:  Mol Biosyst       Date:  2014-10-31

2.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

3.  Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques.

Authors:  Jinhong Ren; Tina L Mistry; Pin-Chih Su; Shahila Mehboob; Robel Demissie; Leslie Wo-Mei Fung; Arun K Ghosh; Michael E Johnson
Journal:  Bioorg Med Chem Lett       Date:  2018-04-22       Impact factor: 2.823

4.  Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.

Authors:  Tatiana Bogdanovich; Catherine Clark; Klaudia Kosowska-Shick; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

5.  Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan.

Authors:  Shahila Mehboob; Kent Truong; Bernard D Santarsiero; Michael E Johnson
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-10-27

6.  Crystal structures and kinetic properties of enoyl-acyl carrier protein reductase I from Candidatus Liberibacter asiaticus.

Authors:  Ling Jiang; Zengqiang Gao; Yanhua Li; Shennan Wang; Yuhui Dong
Journal:  Protein Sci       Date:  2014-02-12       Impact factor: 6.725

7.  Purification, crystallization and preliminary X-ray diffraction analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus mutans strain UA159.

Authors:  Tae-O Kim; Dong-Won Im; Ha Yun Jung; Seong Jung Kwon; Yong-Seok Heo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-02-22

8.  Discovery of a novel and potent class of FabI-directed antibacterial agents.

Authors:  David J Payne; William H Miller; Valerie Berry; John Brosky; Walter J Burgess; Emile Chen; Walter E DeWolf; Andrew P Fosberry; Rebecca Greenwood; Martha S Head; Dirk A Heerding; Cheryl A Janson; Deborah D Jaworski; Paul M Keller; Peter J Manley; Terrance D Moore; Kenneth A Newlander; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Courtney Slater-Radosti; Kevin L Salyers; Mark A Seefeld; Martin G Smyth; Dennis T Takata; Irene N Uzinskas; Kalindi Vaidya; Nicola G Wallis; Scott B Winram; Catherine C K Yuan; William F Huffman
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Biochemical and structural studies of NADH-dependent FabG used to increase the bacterial production of fatty acids under anaerobic conditions.

Authors:  Pouya Javidpour; Jose H Pereira; Ee-Been Goh; Ryan P McAndrew; Suzanne M Ma; Gregory D Friedland; Jay D Keasling; Swapnil R Chhabra; Paul D Adams; Harry R Beller
Journal:  Appl Environ Microbiol       Date:  2013-11-08       Impact factor: 4.792

10.  AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.

Authors:  Krishnamurthy Narasimha Rao; Anirudha Lakshminarasimhan; Sarah Joseph; Swathi U Lekshmi; Ming-Seong Lau; Mohammed Takhi; Kandepu Sreenivas; Sheila Nathan; Rohana Yusof; Noorsaadah Abd Rahman; Murali Ramachandra; Thomas Antony; Hosahalli Subramanya
Journal:  Protein Sci       Date:  2015-04-02       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.